Total Payments
$2,174
2024 Payments
$192.17
Companies
39
Transactions
139
Medicare Patients
22,392
Medicare Billing
$6.0M
Payment Breakdown by Category
Food & Beverage$2,151 (99.0%)
Education$22.72 (1.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $2,151 | 137 | 99.0% |
| Education | $22.72 | 2 | 1.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $436.29 | 31 | $0 (2024) |
| Pharmacyclics LLC, An AbbVie Company | $216.61 | 12 | $0 (2023) |
| Celgene Corporation | $201.57 | 12 | $0 (2024) |
| PFIZER INC. | $122.49 | 12 | $0 (2023) |
| ABBVIE INC. | $121.84 | 5 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $119.44 | 8 | $0 (2021) |
| Merck Sharp & Dohme Corporation | $96.82 | 8 | $0 (2020) |
| ARRAY BIOPHARMA INC | $82.76 | 4 | $0 (2023) |
| Daiichi Sankyo Inc. | $55.51 | 2 | $0 (2023) |
| EMD Serono, Inc. | $55.12 | 3 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $192.17 | 9 | ABBVIE INC. ($80.19) |
| 2023 | $443.10 | 27 | PFIZER INC. ($74.84) |
| 2022 | $243.98 | 14 | E.R. Squibb & Sons, L.L.C. ($46.39) |
| 2021 | $254.14 | 14 | Pharmacyclics LLC, An AbbVie Company ($89.10) |
| 2020 | $97.15 | 5 | Daiichi Sankyo Inc. ($40.81) |
| 2019 | $99.32 | 7 | E.R. Squibb & Sons, L.L.C. ($26.96) |
| 2018 | $517.83 | 37 | E.R. Squibb & Sons, L.L.C. ($127.57) |
| 2017 | $326.37 | 26 | E.R. Squibb & Sons, L.L.C. ($103.29) |
All Payment Transactions
139 individual payment records from CMS Open Payments — Page 2 of 6
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 06/23/2023 | PFIZER INC. | IBRANCE (Drug), PAXLOVID | Food and Beverage | In-kind items and services | $18.29 | General |
| Category: ONCOLOGY | ||||||
| 06/21/2023 | PFIZER INC. | IBRANCE (Drug), PAXLOVID | Food and Beverage | In-kind items and services | $2.12 | General |
| Category: ONCOLOGY | ||||||
| 05/16/2023 | ARRAY BIOPHARMA INC | XALKORI (Drug), LORBRENA, BRAFTOVI | Food and Beverage | In-kind items and services | $25.58 | General |
| Category: ONCOLOGY | ||||||
| 04/26/2023 | PFIZER INC. | IBRANCE (Drug), PAXLOVID | Food and Beverage | In-kind items and services | $13.56 | General |
| Category: ONCOLOGY | ||||||
| 04/26/2023 | PFIZER INC. | INLYTA (Drug), BAVENCIO, XTANDI | Food and Beverage | In-kind items and services | $12.54 | General |
| Category: ONCOLOGY | ||||||
| 04/25/2023 | PFIZER INC. | IBRANCE (Drug), PAXLOVID | Food and Beverage | In-kind items and services | $2.87 | General |
| Category: ONCOLOGY | ||||||
| 04/24/2023 | EMD Serono, Inc. | BAVENCIO (Drug) | Food and Beverage | Cash or cash equivalent | $16.22 | General |
| Category: Oncology | ||||||
| 04/20/2023 | Celgene Corporation | Pomalyst (Drug) | Food and Beverage | Cash or cash equivalent | $13.53 | General |
| Category: Hematology | ||||||
| 02/09/2023 | Celgene Corporation | Pomalyst (Drug) | Food and Beverage | Cash or cash equivalent | $14.70 | General |
| Category: Hematology | ||||||
| 01/30/2023 | CTI BioPharma Corp. | Vonjo (Drug) | Food and Beverage | In-kind items and services | $16.48 | General |
| Category: Hematology | ||||||
| 01/24/2023 | Takeda Pharmaceuticals U.S.A., Inc. | ICLUSIG (Drug) | Food and Beverage | In-kind items and services | $15.51 | General |
| Category: ONCOLOGY | ||||||
| 11/18/2022 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $19.06 | General |
| Category: ONCOLOGY | ||||||
| 09/16/2022 | Pharmacyclics LLC, an AbbVie Company | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $23.33 | General |
| Category: ONCOLOGY | ||||||
| 08/26/2022 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $18.37 | General |
| Category: Hematology | ||||||
| 08/18/2022 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $14.37 | General |
| Category: Oncology | ||||||
| 08/15/2022 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $13.62 | General |
| 08/15/2022 | PFIZER INC. | INLYTA (Drug), BAVENCIO, LORBRENA | Food and Beverage | In-kind items and services | $11.64 | General |
| Category: ONCOLOGY | ||||||
| 06/29/2022 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $18.40 | General |
| 06/11/2022 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $19.51 | General |
| 05/31/2022 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $22.59 | General |
| Category: ONCOLOGY | ||||||
| 03/30/2022 | Celgene Corporation | ONUREG (Drug) | Food and Beverage | Cash or cash equivalent | $17.67 | General |
| Category: Oncology | ||||||
| 02/28/2022 | Pharmacyclics LLC, an AbbVie Company | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $17.86 | General |
| Category: ONCOLOGY | ||||||
| 02/17/2022 | Seagen Inc. | TUKYSA (Drug) | Food and Beverage | In-kind items and services | $22.90 | General |
| Category: Oncology | ||||||
| 02/02/2022 | Novocure Inc. | Optune (Device) | Food and Beverage | Cash or cash equivalent | $12.87 | General |
| Category: Oncology | ||||||
| 01/14/2022 | ARRAY BIOPHARMA INC | BRAFTOVI (Drug), MEKTOVI | Food and Beverage | In-kind items and services | $11.79 | General |
| Category: ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 71 | 5,431 | 132,552 | $5.5M | $1.4M |
| 2022 | 72 | 5,469 | 117,836 | $5.7M | $1.4M |
| 2021 | 75 | 5,951 | 136,901 | $5.6M | $1.6M |
| 2020 | 74 | 5,541 | 146,589 | $6.1M | $1.6M |
Total Patients
22,392
Total Services
533,878
Medicare Billing
$6.0M
Procedure Codes
300
All Medicare Procedures & Services
300 procedure records from CMS Medicare Utilization — Page 1 of 12
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 21 | 9,000 | $1.6M | $389,930 | 24.8% |
| J9299 | Injection, nivolumab, 1 mg | Office | 2023 | 18 | 14,720 | $1.4M | $348,296 | 24.9% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 41 | 7,920 | $497,820 | $146,129 | 29.4% |
| 78815 | Nuclear medicine study from skull base to mid-thigh with ct scan | Office | 2023 | 69 | 74 | $266,478 | $79,932 | 30.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 228 | 737 | $210,045 | $66,013 | 31.4% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 148 | 338 | $121,963 | $31,771 | 26.0% |
| J1439 | Injection, ferric carboxymaltose, 1 mg | Office | 2023 | 34 | 36,000 | $108,003 | $31,505 | 29.2% |
| J2506 | Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | Office | 2023 | 18 | 324 | $234,876 | $27,671 | 11.8% |
| 78816 | Nuclear medicine study whole body with ct scan | Office | 2023 | 24 | 24 | $86,280 | $26,180 | 30.3% |
| 74177 | Ct scan of abdomen and pelvis with contrast | Office | 2023 | 97 | 109 | $78,860 | $17,425 | 22.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 53 | 125 | $46,875 | $16,598 | 35.4% |
| J0885 | Injection, epoetin alfa, (for non-esrd use), 1000 units | Office | 2023 | 20 | 2,580 | $72,560 | $15,155 | 20.9% |
| 88185 | Flow cytometry technique for dna or cell analysis, each additional marker | Office | 2023 | 32 | 779 | $44,447 | $13,732 | 30.9% |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | Office | 2023 | 84 | 89 | $68,975 | $11,503 | 16.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 146 | 193 | $38,793 | $11,303 | 29.1% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 676 | 1,443 | $31,746 | $10,943 | 34.5% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 560 | 959 | $29,735 | $9,896 | 33.3% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 638 | 1,169 | $10,521 | $9,788 | 93.0% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 102 | 382 | $31,080 | $8,239 | 26.5% |
| G0498 | Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | Office | 2023 | 28 | 65 | $22,491 | $7,636 | 33.9% |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | Office | 2023 | 16 | 51 | $71,400 | $6,820 | 9.6% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 83 | 150 | $27,635 | $6,738 | 24.4% |
| 38222 | Biopsy and aspiration of bone marrow sample for diagnosis | Office | 2023 | 52 | 53 | $27,142 | $6,688 | 24.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 64 | 97 | $27,645 | $6,550 | 23.7% |
| 71260 | Ct scan of chest with contrast | Office | 2023 | 110 | 125 | $48,750 | $6,070 | 12.5% |
About Dr. Stacey Knox, MD
Dr. Stacey Knox, MD is a Hematology & Oncology healthcare provider based in Lincoln, Nebraska. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/06/2006. The National Provider Identifier (NPI) number assigned to this provider is 1750353447.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Stacey Knox, MD has received a total of $2,174 in payments from pharmaceutical and medical device companies, with $192.17 received in 2024. These payments were reported across 139 transactions from 39 companies. The most common payment nature is "Food and Beverage" ($2,151).
As a Medicare-enrolled provider, Knox has provided services to 22,392 Medicare beneficiaries, totaling 533,878 services with total Medicare billing of $6.0M. Data is available for 4 years (2020–2023), covering 300 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Lincoln, NE
- Active Since 02/06/2006
- Last Updated 03/16/2024
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1750353447
Products in Payments
- OPDIVO (Biological) $257.99
- IMBRUVICA (Drug) $184.77
- KEYTRUDA (Biological) $96.82
- EMPLICITI (Biological) $84.09
- EPKINLY (Drug) $70.99
- REBLOZYL (Biological) $69.87
- IBRANCE (Drug) $62.30
- XALKORI (Drug) $57.76
- Enhertu (Drug) $55.51
- Revlimid (Drug) $53.59
- Vonjo (Drug) $48.08
- AFINITOR (Drug) $46.14
- VENCLEXTA (Drug) $41.65
- Imbruvica (Drug) $41.04
- FOTIVDA (Drug) $39.71
- ONUREG (Drug) $36.94
- Kyprolis (Biological) $31.43
- Stivarga (Drug) $31.13
- Somatuline Depot (Drug) $29.72
- JEMPERLI (Biological) $28.37
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Lincoln
Mr. Steven Dunder, Md, MD
Hematology & Oncology — Payments: $26,199
Hematology & Oncology $26,199
Nathan Green, Do, DO
Hematology & Oncology — Payments: $10,159
Hematology & Oncology $10,159
Wallace Peterson, Md, MD
Hematology & Oncology — Payments: $6,017
Hematology & Oncology $6,017
Melissa Cetak, Aprn, APRN
Hematology & Oncology — Payments: $5,017
Hematology & Oncology $5,017
Dr. Joni Tilford, Md, MD
Hematology & Oncology — Payments: $4,721
Hematology & Oncology $4,721
Dr. Matthew Shupe, D.o, D.O
Hematology & Oncology — Payments: $4,207
Hematology & Oncology $4,207